Should Patent Remedy Risk Require Action From Liquidia (LQDA) Investors?

Liquidia (NASDAQ:LQDA) Stock Rating Lowered by Wall Street Zen

Stocktwits Wall Street Wrap: Analysts Turn Bullish On Sweetgreen, Target And Airbnb – Liquidia And FICO Face Downgrades

Wells Fargo Downgrades Liquidia to Equal-Weight, Lowers Price Target to $30

Liquidia Shares Tank On Patent Court Loss, Rivals May Just Be Getting Started

HC Wainwright & Co. Maintains Buy on Liquidia, Lowers Price Target to $58

United Therapeutics Just Sent Liquidia Stock Lower After Patent Battle

Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet

LQDA Stock On Track For Worst Week Ever As Analysts Say The Yutrepia Patent Loss Clouds Its Path

Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback

Liquidia Stock Extends Slide Following US Court Ruling in Patent Dispute

UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

United Therapeutics Won Its Patent War and Liquidia Collapsed

Liquidia Sinks Another 17% as BofA Cuts Target to $40 From $92 After Court Loss

Liquidia Stock Crashed 57% in a Day After a Delaware Court Ruling. An Appeal Could Decide Whether Shares Rebound.